The estimated Net Worth of Jill F Schiaparelli is at least 169 千$ dollars as of 20 May 2014. Jill Schiaparelli owns over 2,000 units of Axogen stock worth over 169,320$ and over the last 12 years Jill sold AXGN stock worth over 0$.
Jill has made over 5 trades of the Axogen stock since 2012, according to the Form 4 filled with the SEC. Most recently Jill bought 2,000 units of AXGN stock worth 5,260$ on 20 May 2014.
The largest trade Jill's ever made was buying 5,000 units of Axogen stock on 14 August 2013 worth over 15,000$. On average, Jill trades about 1,821 units every 79 days since 2012. As of 20 May 2014 Jill still owns at least 12,750 units of Axogen stock.
You can see the complete history of Jill Schiaparelli stock trades at the bottom of the page.
Jill's mailing address filed with the SEC is C/O AXOGEN, INC., 13859 PROGRESS BOULEVARD, SUITE 100, ALACHUA, FL, 32615.
Over the last 13 years, insiders at Axogen have traded over 73,805,978$ worth of Axogen stock and bought 504,297 units worth 3,119,117$ . The most active insiders traders include James E Deerfield Mgmt L.P....、Guido J Neels、Karen L. Zaderej. On average, Axogen executives and independent directors trade stock every 21 days with the average trade being worth of 455,132$. The most recent stock trade was executed by John Johnson on 1 September 2024, trading 11,904 units of AXGN stock currently worth 158,085$.
it's time to rethink nerve repair! axogen (nasdaq: axgn) is a medical products company with a portfolio of proprietary products and technologies for peripheral nerve reconstruction and regeneration. people suffer traumatic injuries or undergo surgeries that impact the function of their peripheral nerves daily. damage may cause loss of function and feeling. axogen is bringing the science of nerve repair to life with its avance® nerve graft which axogen believes is the first and only commercially available allograft for bridging nerve discontinuities, axoguard® nerve connector, a coaptation aid allowing for close approximation of severed nerves, and axoguard® nerve protector that protects nerves during the healing process.
Axogen executives and other stock owners filed with the SEC include: